Certuity LLC Sells 15,351 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Certuity LLC trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 11.4% in the 1st quarter, Holdings Channel reports. The fund owned 119,281 shares of the biopharmaceutical company’s stock after selling 15,351 shares during the quarter. Certuity LLC’s holdings in Bristol Myers Squibb were worth $7,275,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Pinney & Scofield Inc. bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $26,000. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth about $28,000. Global Wealth Strategies & Associates increased its stake in shares of Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in Bristol Myers Squibb during the 1st quarter valued at about $31,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $47.82 on Thursday. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The company has a market cap of $97.33 billion, a price-to-earnings ratio of 19.28, a PEG ratio of 2.38 and a beta of 0.36. The company’s 50 day moving average is $47.23 and its 200 day moving average is $51.66. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same quarter last year, the firm posted $2.07 earnings per share. The firm’s revenue was up .6% compared to the same quarter last year. On average, equities research analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.62 per share. The ex-dividend date of this dividend was Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.2%. Bristol Myers Squibb’s payout ratio is currently 100.00%.

Wall Street Analyst Weigh In

BMY has been the subject of a number of analyst reports. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. Jefferies Financial Group reduced their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Finally, Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus target price of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.